¿ËÈÕ£¬ÉϺ£½»Í¨´óѧҽѧԺÁ¥ÊôÉϺ£ÐØ¿ÆÒ½ÔºËï¼ÓÔ´½ÌÊÚÍŶӣ¬¸´µ©´óѧÉϺ£°©Ö¢ÖÐÐÄÀîæ½ÌÊÚÍŶÓÍŽáca88ÉúÎͨ¹ýÖÜÈ«ÆÊÎö·ÎÁ¼¶ñÐÔ½á½ÚµÄDNA¼×»ù»¯Æ×£¬·¢Ã÷Äܹ»Çø±ðÕâÁ½Àà½á½ÚµÄ²î±ðÐÔDNA¼×»ù»¯ÇøÓò£¬²¢¿ª·¢ÁËÒ»ÖÖ»ùÓÚ¼×»ù»¯°ÐÏò²âÐòÊÖÒÕµÄÐÂÐͷνá½ÚÕï¶Ï¹¤¾ßLUNG-TRAC¡£Ïà¹ØÑо¿Ð§¹ûÒÔ“Non-invasive diagnosis of pulmonary nodules by circulating tumor DNA methylation: A prospective multicenter study”ΪÌ⣬ÔÚÏß½ÒÏþÓÚ¾Û½¹ºôÎüϵͳ°©Ö¢µÄ¹ú¼ÊÆÚ¿¯Lung Cancer£¨IF 4.5)[1]¡£
µÍ¼ÁÁ¿ÅÌËã»ú¶Ï²ãɨÃ裨LDCT£©¶ÔÔçÆÚ¶ñÐԷνá½Ú¾ßÓиßѸËٶȣ¬Òò´ËÆÕ±éÓÃÓÚ¼ì²âÔçÆڷΰ©¡£µ«LDCTÒ²ÓкܸߵļÙÑôÐÔÂÊ£¬ÀýÈçµÄ¹ú¼Ò·Î°©É¸²éÊÔÑ飨NLST£©Ñо¿·¢Ã÷LDCT¶ÔÁ¼ÐԷνá½ÚµÄ¼ÙÑôÐÔÂÊ¿ÉÒԸߴï96.4%[2]£¬µ¼ÖÂÁËÒ»¶¨ÃüÄ¿µÄ²»ÐëÒªµÄÊÖÊõÖÎÁÆ¡£Òò´Ë£¬ÁÙ´²ÉÏÓÐÐëÒª¶ÔLDCT¼ì²âµ½µÄ½á½Ú¾ÙÐнøÒ»²½µÄ¶ñÐÔΣº¦Õ¹ÍûºÍ·Ö²ã£¬ÓÃÓÚ¸¨ÖúºóÐøµÄÒ½ÁƾöÒ飨ÊÖÊõ»òËæ·Ã£©¡£ÏÖÔÚÁÙ´²ÉÏÒѾ¿ª·¢µÄ¼¸ÖÖ·ÇÇÖÈëÐԷνá½Ú¶ñÐÔΣº¦Õ¹ÍûºÍ·Ö²ãÄ£×Ó£¬ÈçMayoÕïËùÄ£×Ó£¨MayoÄ£×Ó£©[3]ºÍÍËÎéÎäÊ¿ÖÎÀí¾ÖÄ£×Ó£¨VAÄ£×Ó£©[4]µÈ£¬ÔÚÑéÖ¤Ñо¿ÖеÄ׼ȷÐÔÉÐÓв»Ð¡µÄˢпռ䡣Òò´Ë£¬ÔÚÁÙ´²Êµ¼ùÖÐÒýÈë¸ü׼ȷµÄ·Î½á½ÚΣº¦Õ¹ÍûºÍ·Ö²ãÊÖÒÕ½«ÓÐÖúÓÚïÔÌÌ«¹ýÕï¶Ï£¬½µµÍÏà¹ØµÄÒ½ÁƼ縺¡£
¡¸Ñо¿ÁÁµã¡¹
3. ¾ÙÐÐLUNG-TRACµ¥ÖÐÐĺͶàÖÐÐĵ¥Ã¤ÐÔÄÜÑéÖ¤£¬Ö¤Êµ¸ÃÄ£×Ó¼á³ÖÁ˶ÔÁ¼ÐԷνá½ÚµÄ¸ßÌØÒìÐÔ£¬Äܹ»ïÔ̲»ÐëÒªµÄÊÖÊõ¸ÉÔ¤£¬²¢ÇÒ×ÜÌåÐÔÄÜÏÔÖøÓÅÓÚMayoºÍVAÄ£×Ó¡£
¡¸Ñо¿ÒªÁ졹
¸ÃÑо¿¹²°üÀ¨Ëĸö½×¶Î£¨Í¼1£©£º±ê¼ÇÎïµÄ·¢Ã÷ÓëÓÅ»¯£¬LUNG-TRACÄ£×Ó¹¹½¨ÓëÑéÖ¤£¬µ¥ÖÐÐĺͶàÖÐÐĵ¥Ã¤²âÊÔ£¨Í¼1£©¡£µÚÒ»½×¶Î£º±ê¼ÇÎïµÄ·¢Ã÷ÓëÓÅ»¯¡£Ê×ÏÈ£¬Ê¹ÓÃRRBSÊÖÒÕ£¬¶Ô·Î°©×éÖ¯ºÍÁ¼ÐԷνá½Ú×éÖ¯¾ÙÐÐÈ«»ùÒò×é¼×»ù»¯¾ÙÐвâÐòºÍÆÊÎö£¬·¢Ã÷Äܹ»Çø·ÖÁ¼ÐԺͶñÐԷνá½ÚµÄDMR£¬²¢Ñ¡È¡ÆäÖÐ80¸öÓëÆäËûȪԴµÄ¼×»ù»¯±ê¼ÇÎïÒ»Æð×÷Ϊ±ê¼ÇÎ±»¿ª·¢Îª¼×»ù»¯°ÐÏò²âÐòpanel¡£µÚ¶þ½×¶Î£ºÑµÁ·²¢ÑéÖ¤LUNG-TRACÄ£×Ó¡£Ê¹ÓÃÉÏÊöpanel£¬¶Ô183ÀýÀ´×ÔÉϺ£ÐØ¿ÆÒ½ÔºµÄÁ¼ÐÔ»ò¶ñÐԷνá½Ú»¼ÕßµÄcfDNA¾ÙÐмì²â£¬²¢Æ¾Ö¤panelÖбê¼ÇÎïÔÚÁ½ÀàcfDNAÖм׻ù»¯Ë®Æ½µÄ²î±ðѵÁ··Î½á½ÚΣº¦Õ¹ÍûºÍ·Ö²ãÄ£×ÓLUNG-TRAC£¬²¢ÔÚÒ»¸ö62Ãû»¼ÕßÐÐÁÐÖоÙÐÐÁËÑéÖ¤£¬²¢ÓëMayoºÍVAΣº¦·Ö²ãÄ£×Ó½ÏÁ¿ÐÔÄÜ¡£µÚÈý½×¶Î£ºµ¥ÖÐÐIJâÊÔLUNG-TRACÐÔÄÜ¡£Ê¹ÓÃLUNG-TRAC¶Ô61ÀýÀ´×ÔÉϺ£ÐØ¿ÆÒ½ÔºµÄ×ÔÁ¦·Î½á½Ú»¼ÕßÐÐÁеÄcfDNA¾ÙÐмì²â²¢ÒÔµ¥Ã¤·½·¨Õ¹ÍûÕâЩ½á½ÚµÄÁ¼¶ñÐÔ£¬²¢¼ÌÐøÓëMayoºÍVAΣº¦Ä£×Ó½ÏÁ¿ÐÔÄÜ¡£µÚËĽ׶Σº¶àÖÐÐIJâÊÔLUNG-TRACÐÔÄÜ¡£Ê¹ÓÃLUNG-TRAC¶Ô95ÀýÀ´×Ô4¼Ò²î±ðµÄÒ½ÔºµÄ·Î½á½Ú»¼ÕßÐÐÁеÄcfDNA¾ÙÐмì²â£¬²¢ÒÔµ¥Ã¤·½·¨Õ¹ÍûÁ¼¶ñÐÔ¡£
ͼ1£ºÑо¿Á÷³Ì¸ÅÊö
¡¸Ñо¿Ð§¹û¡¹
1.·¢Ã÷Äܹ»Çø·ÖÁ¼ÐԺͶñÐԷνá½Ú×éÖ¯µÄDMR
ʹÓÃRRBSÊÖÒÕ£¬¶Ô30Àý·Î°©×éÖ¯ºÍ24ÀýÁ¼ÐԷνá½Ú×éÖ¯¾ÙÐÐÈ«»ùÒò×é¼×»ù»¯¾ÙÐвâÐò¡£²¢ÔÚ¶à´ÎʵÑéºó£¬Ñ¡¶¨PDR£¨Proportion of Discordant Reads£©×÷ΪȨºâ¼×»ù»¯Ë®Æ½ºÍÄ£×ӵĶ¨Á¿Ö¸±ê£¬¶ÔÕâЩ·Î½á½Ú×éÖ¯µÄ¼×»ù»¯Í¼Æ¬¾ÙÐÐÆÊÎöºÍ½ÏÁ¿£¬´ÓÖз¢Ã÷Á˽ü7000¸öÄܹ»Çø·ÖÁ¼ÐԺͶñÐԷνá½ÚµÄDMR¡£½øÒ»²½Ñ¡³öÆäÖÐ80¸ö¸ßÖÃÐŶȵÄDMR£¬ÓëÆäËûȪԴµÄ¼×»ù»¯±ê¼ÇÎïÒ»Æð×é³É760¸ö±ê¼ÇÎÓÃÓÚ¿ª·¢·Î½á½ÚΣº¦Õ¹ÍûºÍ·Ö²ãµÄ¼×»ù»¯°ÐÏò²âÐòpanel¡£
ͼ2£º£¨A£©ÎÞ¼àÊÓ¾ÛÀàÆÊÎöºÍ£¨B£©Ö÷ÒòËØÆÊÎö¾ùÏÔʾ´ÓRRBSÊý¾ÝÖÐÑ¡³öµÄ80¸öDMRÄܽ«Á¼ÐÔ½á½Ú¡¢ÏÙ°©£¨ADC£©ºÍÁÛ״ϸ°û°©£¨SCC£©×éÖ¯ÇåÎúµØÊèÉ¢¡£
2.LUNG-TRACÄ£×ÓѵÁ·¡¢ÑéÖ¤ºÍµ¥ÖÐÐIJâÊÔЧ¹ûÏÔʾÆä¾ßÓнϺõķº»¯ÐÔÄÜ
306¸öÀ´×ÔÉϺ£ÐØ¿ÆÒ½ÔºµÄ·Î½á½Ú²¡ÀýÓÃÓÚΣº¦·Ö²ãÄ£×Ó¿ª·¢¡£·Î½á½ÚµÄ¾¶³¤¹æģΪ5-30ºÁÃס£ÕâЩ»¼Õß±»Ëæ»ú·ÖΪÈý¸öÐÐÁУºÑµÁ·¼¯£¨N=183£©¡¢ÑéÖ¤¼¯£¨N=62£©ºÍµ¥ÖÐÐIJâÊÔ¼¯£¨N=61£©¡£¸÷ÜöÝͳÉÔ±µÄ×é˽¼ûͼ1£¬×¢ÖØÿ¸öÜöÝÍÖв»µ«°üÀ¨²¡ÀíÈ·ÕïµÄÔçÆڷΰ©£¨Ôλ°©ÖÁIBÆÚ£¬¼òдΪPMal£©ºÍÁ¼ÐԷνá½Ú£¨¼òдΪPBe£©£¬»¹°üÀ¨Æ¾Ö¤ÁÙ´²Ö¸±ê¡¢×¨¼Ò»áÕïºÍºã¾ÃËæ·ÃЧ¹ûÕï¶ÏµÄ¶ñÐԷνá½Ú£¨¼òдΪCMal£©ºÍÁ¼ÐԷνá½Ú£¨¼òдΪCBe£©¡£
Ê×ÏÈʹÓü׻ù»¯°ÐÏò²âÐòpanel¼ì²âѵÁ·¼¯»¼Õߣ¨39¸öCBe¡¢20¸öPBe¡¢37¸öCMalºÍ87¸öPMal£©µÄcfDNAÑù±¾£¬²¢È·¶¨ËùÓбê¼ÇÎïµÄPDRÖµ£¬²¢Ì½Ë÷Á˶àÖÖ½¨Ä£ÒªÁìÖÐËüÃǵķÖÀàÄÜÁ¦£¬×îÖÕÈ·¶¨Ê¹ÓÃÂß¼»Ø¹é£¨logistic regression£¬¼ò³ÆLR£©ÒªÁ콨Éè·Î½á½Ú¶ñÐÔΣº¦Õ¹ÍûºÍ·Ö²ãÄ£×Ó¡£ÔÚ²âÊÔÁ˲î±ðµÄLRãÐÖµºÍ½¨Ä£²ÎÊý×éºÏºó£¬²¢²âÊÔÁËÿÖÖ×éºÏѵÁ·³öÀ´µÄÄ£×Ӻ󣬶ÔѵÁ·¼¯Ñù±¾¾ßÓÐ×î¸ß·ÖÀà׼ȷÐÔµÄÄ£×Ó£¨AUC=0.973£¬Ñ¸ËÙ¶È=94.4%£¬ÌØÒìÐÔ=88.1%£©±»Ñ¡¶¨ÓÃÓÚºóÐøÑéÖ¤ºÍ²âÊÔ£¬²¢ÃüÃûΪLUNG-TRAC¡£
LUNG-TRACµÄÁ¼¶ñÐԷνá½ÚÕ¹ÍûÐÔÄÜÊ×ÏÈÔÚÒ»¸ö×ÔÁ¦µÄ62¸öѪ½¬Ñù±¾ÐÐÁУ¨12¸öCBe£¬7¸öPBe£¬8¸öCMalºÍ35¸öPMal£©¾ÙÐÐÁËÑéÖ¤£¬ÆäAUCֵΪ0.810£¨Ñ¸ËÙ¶È=74.4%£¬ÌØÒìÐÔ=73.7%£©£¨Í¼3£©¡£ËæºóʹÓÃÁíÒ»¸ö×ÔÁ¦µÄ°üÀ¨61¸öѪ½¬Ñù±¾£¨12¸öCBe£¬9¸öPBe£¬5¸öCMalºÍ35¸öPMal£©µÄÐÐÁжÔLUNG-TRAC¾ÙÐÐÁ˵¥Ã¤²âÊÔ£¬ÆäAUCÖµ0.815£¨Ñ¸ËÙ¶È=67.5%£¬ÌØÒìÐÔ=76.2%£©¡£¿É¼ûLUNG-TRACÔÚÑéÖ¤¼¯ºÍµ¥ÖÐÐIJâÊÔ¼¯ÖÐÏÔʾ³öÎȹ̵ÄÐÔÄÜ£¬Æä¶Ô·Î½á½ÚÁ¼¶ñÐÔµÄÕ¹ÍûѸËٶȺÍÌØÒìÐÔ½ÏΪһÖ£¬ÌáÐѸÃÄ£×ÓÓнϺõķº»¯ÄÜÁ¦¡£
ͼ3£º£¨A£©LUNG-TRACÄ£×ÓÔÚѵÁ·¼¯¡¢ÑéÖ¤¼¯ºÍµ¥ÖÐÐIJâÊÔ¼¯ÖжԷνá½ÚcfDNAÑù±¾Á¼¶ñÐÔÕ¹ÍûЧ¹ûµÄROCÇúÏߺÍAUCÖµ£¨B£©LUNG-TRACÄ£×Ó¶ÔѵÁ·¼¯¡¢ÑéÖ¤¼¯ºÍµ¥ÖÐÐIJâÊÔ¼¯ÖÐÁ¼ÐԷνá½ÚºÍ·Î°©»¼ÕßcfDNAÑù±¾µÄ¶ñÐÔˮƽչÍûÖµµÄÂþÑÜÇéÐΣ¬ºÍÁ¼ÐÔ-¶ñÐÔ½á½ÚÑù±¾Ö®¼ä·ÖÖµ²î±ðµÄÏÔÖøÐÔ¡£
3.¶àÖÐÐIJâÊÔ֤ʵLUNG-TRACÄ£×Ó¶ÔÁ¼ÐԷνá½ÚÑù±¾¾ßÓнϸߵÄÌØÒìÐÔ
ΪÁ˽øÒ»²½ÆÀ¹ÀLUNG-TRACµÄ׼ȷÐÔºÍÎȹÌÐÔ£¬LUNG-TRAC¶ÔÀ´×ÔËļÒÒ½Ôº£¨ÉϺ£ÐØ¿ÆÒ½Ôº¡¢ÎÞÎýµÚ¶þÈËÃñÒ½Ôº¡¢Õã½´óѧҽѧԺÁ¥ÊôÉÛÒÝ·òÒ½ÔººÍºÓÄÏÊ¡ÈËÃñÒ½Ôº£©µÄÓÉ95Ãû·Î½á½Ú»¼Õߣ¨12¸öCBe¡¢14¸öPBe¡¢3¸öCMalºÍ66¸öPMal£©×é³ÉµÄÇ°Õ°ÐÔÐÐö¾ÙÐÐÁËä²â¡£Õâ´Î²âÊÔÖУ¬LUNG-TRAC¶Ô·Î½á½ÚÁ¼¶ñÐÔÕ¹ÍûµÄAUCֵΪ 0.761£¨Ñ¸ËÙ¶È=50.7%£¬ÌØÒìÐÔ=80.8%£©£¨Í¼4£©£¬ÕâÓëÑéÖ¤ºÍµ¥ÖÐÐIJâÊÔµÄЧ¹ûÒ»Ö£¨AUC»®·ÖΪ0.810ºÍ0.815£©¡£Ö÷ÒªµÄÊÇ£¬LUNG-TRACÔÚ¶àÖÐÐIJâÊÔÖмá³ÖÁ˸ßÌØÒìÐÔ£¨80.8%£©£¬ÓëÑéÖ¤¼¯ºÍµ¥ÖÐÐIJâÊÔ¼¯µÄÌåÏÖºÜÊÇÒ»Ö£¨ÌØÒìÐÔ»®·ÖΪ73.7%ºÍ76.2%£©£¬Ö¤ÊµÁ˸ÃÄ£×Ó¶ÔÁ¼ÐÔ½á½Ú¾ßÓнϺõÄÌØÒìÐÔ£¬Äܹ»ÓÐÓõØïÔ̽«Á¼ÐÔ½á½ÚÎóÕïΪ¶ñÐԵı¬·¢¡£
ͼ4£º£¨A£©LUNG-TRACÄ£×ÓÔÚ¶àÖÐÐIJâÊÔ¼¯ÖжԷνá½ÚcfDNAÑù±¾Á¼¶ñÐÔÕ¹ÍûЧ¹ûµÄµÄROCÇúÏߺÍAUCÖµ£¨B£©LUNG-TRACÄ£×Ó¶Ô¶àÖÐÐIJâÊÔ¼¯ÖÐÁ¼ÐԷνá½ÚºÍ·Î°©»¼ÕßcfDNAÑù±¾µÄ¶ñÐÔˮƽչÍûÖµµÄÂþÑÜÇéÐΣ¬ºÍÁ¼ÐÔ-¶ñÐÔ½á½ÚÑù±¾Ö®¼ä·ÖÖµ²î±ðµÄÏÔÖøÐÔ¡£
4.LUNG-TRAC¶Ô·Î½á½Ú¶ñÐÔΣº¦Õ¹ÍûºÍ·Ö²ãµÄÐÔÄÜÏÔÖøÓÉÓÚMayoºÍVAÄ£×Ó
MayoÄ£×ÓºÍVAÄ£×Ó¾ùʹÓÃÁÙ´²ÐÅÏ¢ºÍ·ÅÉäѧÌØÕ÷£¬ÈçÄêËê¡¢ÎüÑÌÊ·¡¢½á½Ú¾Þϸ¡¢Î»ÖúÍÐÎ×´£¬×÷Ϊģ×Ó²ÎÊýÀ´Á¿»¯·Î½á½Ú¶ñÐÔΣº¦¡£Æ书ЧÓëLUNG-TRAC»ùÄÚÇéͬ¡£
ÔÚ±¾Ñо¿ÖУ¬MayoÄ£×ÓºÍVAÄ£×ÓÔÚÑéÖ¤¼¯ÖеÄAUC»®·ÖΪ0.564£¨Ñ¸ËÙ¶È=47.6%£¬ÌØÒìÐÔ=57.9%£©ºÍ0.539£¨Ñ¸ËÙ¶È=33.3%ºÍÌØÒìÐÔ=63.2%£¬Í¼5B£©¡£ÔÚµ¥ÖÐÐIJâÊÔÖУ¬MayoÄ£×ÓºÍVAÄ£×ÓµÄÌåÏÖÓëÑéÖ¤¼¯ÏàËÆ£¬»®·ÖΪAUC 0.588£¨Ñ¸ËÙ¶È=59.0%£¬ÌØÒìÐÔ=73.7%£©ºÍ0.554£¨Ñ¸ËÙ¶È=38.5%£¬ÌØÒìÐÔ=78.9%£©£¨Í¼5C£©¡£Òò´Ë£¬ÓëLUNG-TRACÏà±È£¬MayoÄ£×ÓºÍVAÄ£×ÓÔÚÑéÖ¤ºÍµ¥ÖÐÐIJâÊÔÖеÄAUCµÃ·ÖÏÔÖø½ÏµÍ£¬ÌáÐÑLUNA-TRACµÄ×ÜÌåÐÔÄÜÏÔÖøÓÉÓÚÕâÁ½¸ö³£Óõķνá½Ú¶ñÐÔΣº¦·Ö²ãÄ£×Ó¡£
ͼ5£ºLUNG-TRAC¡¢Mayo¡¢VAºÍÇ°ÈýÕߺϲ¢½¨ÉèµÄÄ£×Ó£¨Combined£©ÔÚ£¨A£©ÑéÖ¤¼¯£¬£¨B£©µ¥ÖÐÐIJâÊÔ¼¯ºÍ£¨C£©¶àÖÐÐIJâÊÔ¼¯ÖжԷνá½ÚcfDNAÑù±¾Á¼¶ñÐÔÕ¹ÍûЧ¹ûµÄROCÇúÏߺÍAUCÖµ¡££¨D£©ºÏ²¢Ä£×Ó¶ÔѵÁ·¼¯¡¢ÑéÖ¤¼¯ºÍµ¥ÖÐÐIJâÊÔ¼¯ÖÐÁ¼ÐԷνá½ÚºÍ·Î°©»¼ÕßcfDNAÑù±¾µÄ¶ñÐÔˮƽչÍûÖµµÄÂþÑÜÇéÐΣ¬ºÍÁ¼ÐÔ-¶ñÐÔ½á½ÚÑù±¾Ö®¼ä·ÖÖµ²î±ðµÄÏÔÖøÐÔ¡£
¡¸½áÓ
LUNG-TRAC·Î½á½Ú¶ñÐÔΣº¦Õ¹ÍûºÍ·Ö²ãÄ£×Ó¾ÓÉÁË°üÀ¨Ê¹ÓÃÇ°Õ°ÐÔÐÐÁеĶàÖÐÐIJâÊÔÔÚÄڵĶàÂÖÑéÖ¤ºÍ²âÊÔºó£¬Ö¤ÊµÎú¾ßÓнϸߵÄÌØÒìÐÔͬʱ¼á³Ö½ÏºÃµÄѸËٶȡ£Òò´Ë¸ÃÄ£×ÓÄܹ»×ÊÖúÁÙ´²Ò½ÉúïÔ̶ÔÁ¼ÐÔ½á½Ú»¼ÕߵIJ»ÐëÒªµÄ¸ÉÔ¤£¬ÌØÊâÊÇïÔ̶Էνá½Ú»¼ÕßÉúÑÄÖÊÁ¿±¬·¢µ¹ÔËÓ°ÏìµÄÇÖÈëÐÔÊÖÊõ£¬Í¬Ê±·¢Ã÷²¢ÊµÊ±ÖÎÁƶñÐÔ»ò¸ßΣº¦·Î½á½Ú²¡Àý£¬´Ó¶ø´ÓÕûÌåÉϸÄÉÆËùÓзνá½Ú»¼ÕßµÄÁÙ´²Ð§¹û£¬¸üÓÐÓõØʹÓÃÏÖÓÐÁÙ´²×ÊÔ´¡£
¡¸²Î¿¼ÎÄÏס¹
[1] Y. Li et al., "Non-invasive diagnosis of pulmonary nodules by circulating tumor DNA methylation: A prospective multicenter study," Lung Cancer, vol. 195, p. 107930, Sep 2024.
[2] T. National Lung Screening Trial Research et al., "Reduced lung-cancer mortality with low-dose computed tomographic screening," N Engl J Med, vol. 365, no. 5, pp. 395-409, Aug 4 2011.
[3] S. J. Swensen, M. D. Silverstein, D. M. Ilstrup, C. D. Schleck, and E. S. Edell, "The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules," Arch Intern Med, vol. 157, no. 8, pp. 849-55, Apr 28 1997.
[4] M. K. Gould et al., "Recent Trends in the Identification of Incidental Pulmonary Nodules," Am J Respir Crit Care Med, vol. 192, no. 10, pp. 1208-14, Nov 15 2015.
±¾ÎÄ°üÀ¨µÄËùÓÐÄÚÈݽö¹©×¨ÒµÈËÊ¿ÔĶÁ¼Î¿½å¼£¬·Ç¹ã¸æÓÃ;¡£